Archer-Daniels-MidlandADM
ADM logo
Fair Value
US$60
Share price23 Jul
US$76.5927.7% overvalued intrinsic discount
Loading
1Y32.42%
7D-3.38%

Biofuel Policy Dependence And Cost Pressures Will Constrain Future Earnings Potential

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
22 Apr 26
Updated
23 Jul 26
Views
15
Not Invested

Last Update 23 Jul 26

Fair value Increased 20%

ADM: Elevated P/E Assumptions Will Increase Downside Risk If Earnings Disappoint

Analysts have raised their Archer-Daniels-Midland fair value estimate to $60 from $50, reflecting updated views on revenue growth, profit margins, and future P/E after a series of recent price target increases across the Street.

Analyst Commentary

Recent Street commentary on Archer-Daniels-Midland points to a mixed backdrop, with several firms adjusting price targets while keeping a cautious tone on the stock's risk and reward balance.

One major firm lifted its Archer-Daniels-Midland price target to US$60 from US$58 but kept an Underweight rating, signaling that, in its view, the stock still does not fully stack up against other options in the sector. That firm outlined expectations for potential Q2 results that differ from current consensus assumptions and modestly adjusted its 2026 earnings outlook. However, its projections remain below broader market estimates for both 2026 and 2027.

Other bearish analysts have also raised Archer-Daniels-Midland price targets in recent months, including increases to US$58 from US$54 and multi-dollar upward revisions from several firms. Even with these moves, the tone across these updates remains measured, pointing to ongoing questions around how much upside is already reflected in the stock price.

Bearish Takeaways

  • Bearish analysts, including a major firm that kept an Underweight rating at a US$60 price target, see limited upside relative to other stocks, which can cap near-term rerating potential for Archer-Daniels-Midland.
  • Where detailed, earnings projections for 2026 and 2027 sit below consensus, highlighting concerns that Archer-Daniels-Midland may struggle to fully meet the market's current growth and margin expectations.
  • The sequence of cautious price target adjustments, including those from large firms such as JPMorgan, still reflects hesitation around paying higher P/E multiples before there is clearer evidence on execution and long-term earnings power.
  • Bearish analysts implicitly flag valuation risk, suggesting that if Archer-Daniels-Midland falls short of consensus forecasts, there could be pressure on both earnings expectations and the multiple investors are willing to assign.

What’s in the News for Archer-Daniels-Midland

  • Archer-Daniels-Midland appointed Jeff Rowe as Executive Vice President and Chief Operating Officer, effective August 17, 2026, with responsibility for commercial businesses, global manufacturing, and R&D, according to company announcements.
  • General Mills, Archer-Daniels-Midland, and Walmart launched a collaboration to support regenerative agriculture across 40,000 wheat acres in the Midwest, focusing on practices such as cover crops and no-till farming to improve soil health, water quality, and carbon sequestration, with ADM providing technical assistance and financial incentives to growers.
  • Archer-Daniels-Midland plans to release Q2 2026 financial results on August 4, with an accompanying webcast and press materials. The company recently updated full year adjusted EPS guidance to US$4.15 to US$4.70, supported by its crushing and ethanol businesses and U.S. biofuels policy changes, according to analyst summaries.
  • Recent coverage highlights Archer-Daniels-Midland stock performance over the past year and year to date, with commentary tying this to earnings expectations, a favorable Zacks Rank, portfolio actions, cost discipline, and a focus on higher margin, value added products, as well as digital and supply chain initiatives.
  • Archer-Daniels-Midland shares recently reached a 52 week high of US$83.20 after Q1 2026 adjusted EPS of US$0.71 compared with forecasts of US$0.68. Analysts and media reports also noted raised full year adjusted EPS guidance, ongoing productivity and BioSolutions initiatives, and discussion of valuation and insider selling.

Valuation Changes for Archer-Daniels-Midland

  • Fair Value: Raised from $50.00 to $60.00, a 20.0% increase in the analyst fair value estimate.
  • Discount Rate: Edged higher from 6.98% to 7.11%, reflecting a slightly higher required return in the model.
  • Revenue Growth: Assumed growth rate increased from 0.94% to 1.23%, indicating a higher modeled top line expansion for Archer-Daniels-Midland.
  • Profit Margin: Projected net profit margin moved from 2.51% to 2.89%, implying a modestly stronger earnings profile on each $1 of revenue.
  • Future P/E: Forward P/E assumption rose from 14.31x to 14.81x, a small uptick in the valuation multiple applied to future earnings.
7 viewsusers have viewed this narrative update

Catalysts

About Archer-Daniels-Midland

Archer-Daniels-Midland is a global agricultural processor and ingredient company with businesses in Ag Services and Oilseeds, Carbohydrate Solutions and Nutrition.

What are the underlying business or industry changes driving this perspective?

  • Reliance on U.S. biofuel policy clarity and Renewable Volume Obligations creates a risk that any delay or smaller than expected mandate keeps crush margins subdued for longer, which would restrain AS&O revenue and earnings power relative to what current pricing may imply.
  • Consumer shifts toward lower packaged food consumption, concern about ultra processed foods and GLP 1 adoption are pressuring Starches and Sweeteners volumes and pricing, which could cap Carbohydrate Solutions revenue and weigh on segment margins if these behavior patterns persist.
  • Nutrition segment growth is heavily tied to ramps in Flavors, Specialty Ingredients and biotics at a time when recent operating profit in Human Nutrition fell due to the absence of insurance proceeds, so slower than expected customer win backs and portfolio recovery could limit group earnings expansion.
  • Higher structural manufacturing costs in North America for energy, labor and contractors, along with a large plant footprint, mean cost savings may take longer to materialize, which would keep net margins under pressure even if volumes improve.
  • Large planned capital expenditures of US$1.3b to US$1.5b in 2026 and a cost savings target of US$500m to US$750m over 3 to 5 years depend on successful execution in areas like decarbonization, carbon capture and biosolutions. Any delays or cost overruns could dilute returns on invested capital and slow EPS growth.
NYSE:ADM Earnings & Revenue Growth as at Apr 2026
NYSE:ADM Earnings & Revenue Growth as at Apr 2026

Assumptions

How have these above catalysts been quantified?

  • This narrative explores a more pessimistic perspective on Archer-Daniels-Midland compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
  • The bearish analysts are assuming Archer-Daniels-Midland's revenue will grow by 1.2% annually over the next 3 years.
  • The bearish analysts assume that profit margins will increase from 1.3% today to 2.9% in 3 years time.
  • The bearish analysts expect earnings to reach $2.4 billion (and earnings per share of $5.02) by about July 2029, up from $1.1 billion today. The analysts are largely in agreement about this estimate.
  • In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 14.8x on those 2029 earnings, down from 38.9x today. This future PE is lower than the current PE for the US Food industry at 17.6x.
  • The bearish analysts expect the number of shares outstanding to grow by 0.31% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

  • ADM is targeting the next wave of growth from enhanced nutrition, biotics, biosolutions, precision fermentation and decarbonization, and management describes these as opportunities for compelling enduring returns. If these platforms gain traction, they could support higher long term revenue and earnings than a bearish view assumes.
  • Record crush volumes in South America, strong ethanol EBITDA margins per gallon that are approximately 33% higher than the prior year quarter, and robust ethanol export demand supported by mandated markets, suggest ADM can still benefit from long term biofuel demand. This could help offset softer Starches and Sweeteners volumes and support segment operating profit and cash flow.
  • Nutrition is already seeing strong North America flavor sales, recovery in Specialty Ingredients and margin expansion in Animal Nutrition after portfolio streamlining. If this recovery continues and the Alltech joint venture scales, Nutrition could become a larger profit contributor and support higher group operating profit and earnings.
  • Management reports approximately US$200m of cost savings already achieved in 2025, a targeted US$500m to US$750m in aggregate savings over 3 to 5 years, and better working capital management that delivered a US$1.5b cash flow benefit from inventory reduction. If these efforts continue, they could lift net margins and support higher earnings even if volumes stay under pressure.
  • Closure of government investigations related to prior intersegment sales reporting, restoration of the Decatur East plant, and connection of the Columbus, Nebraska facility to the Trailblazer carbon capture pipeline remove significant operational and regulatory overhangs. This could reduce risk, support decarbonization related revenue opportunities and help sustain ADM's long running dividend record and cash generation.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The assumed bearish price target for Archer-Daniels-Midland is $60.0, which represents up to two standard deviations below the consensus price target of $75.3. This valuation is based on what can be assumed as the expectations of Archer-Daniels-Midland's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $95.0, and the most bearish reporting a price target of just $60.0.
  • In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $83.6 billion, earnings will come to $2.4 billion, and it would be trading on a PE ratio of 14.8x, assuming you use a discount rate of 7.1%.
  • Given the current share price of $87.32, the analyst price target of $60.0 is 45.5% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Archer-Daniels-Midland?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$60
vs US$76.5927.7% overvalued intrinsic discount
PastFuture0100b2015201820212024202620272029Revenue US$83.6bEarnings US$2.4b
1.2%
Revenue growth
2.9%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Archer-Daniels-Midland

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet established dividend payer.

Market capUS$36.9b
PB1.6x
Estimated Growth2.6%
Dividend Yield2.7%
Full analysis

CEO & management

Juan Luciano
CEO
2.8yrs
CEO Tenure

Provides human and animal nutrition ingredients and solutions in the United States, Switzerland, the Cayman Islands, Brazil, Mexico, Canada, the United Kingdom, and internationally.